Basisstatistiken
| CIK | 1812364 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Relay Therapeutics, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 21, 2026 |
22,916,667 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 21, 2026 |
EX-1.1 Exhibit 1.1 Execution Version RELAY THERAPEUTICS, INC. 22,916,667 Shares of Common Stock, par value $0.001 per share Underwriting Agreement May 20, 2026 Jefferies LLC TD Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New Yor |
|
| May 21, 2026 |
Calculation of Filing Fee Tables S-3 Relay Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| May 19, 2026 |
Vascular Anomalies Update May 2026 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress, timing and results of the clinical development of the programs across our portfolio, including the expected timin |
|
| May 19, 2026 |
Subject To Completion Dated May 19, 2026 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 19, 2026 |
Exhibit 99.1 Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-r |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| May 5, 2026 |
Exhibit 99.1 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 28, 2026 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) շ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2025 OR ն TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 FORTHETRANSITIONPERIODFROM TO CommissionFileNumber:001-39385 RELAYTHERAPEUTICS,INC. (ExactnameofRegistrantasspecifiedinitsCha |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| April 27, 2026 |
Exhibit 99.1 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-exper |
|
| April 27, 2026 |
Zovegalisib Triplet Disclosure April 2026 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress and timing of the clinical development of the programs across our portfolio, including the expected timing |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| March 16, 2026 |
Exhibit 99.1 Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Efficacy in patients with |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2026 |
SECOND AMENDED AND RESTATED RELAY THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF RELAY THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEU |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 26, 2026 |
As filed with the Securities and Exchange Commission on February 26, 2026 As filed with the Securities and Exchange Commission on February 26, 2026 Registration No. |
|
| February 26, 2026 |
Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg |
|
| February 26, 2026 |
Calculation of Filing Fee Table Form S-8 (Form Type) Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Relay Therapeutics, Inc. |
|
| February 26, 2026 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Relay Securities Corporation Massachusetts |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2026 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 3, 2026 |
Exhibit 99.1 Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase |
|
| November 6, 2025 |
Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company’s Board of Directors Approximately $596 million in cash, cash equiv |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| August 7, 2025 |
Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of |
|
| August 7, 2025 |
Exhibit 10.2 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of June 3, 2025, by and between ARE-MA REGION NO. 58, LLC, a Delaware limited liability company (“Landlord”), and RELAY THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as January 10, 2018, as amended by |
|
| August 7, 2025 |
Amended and Restated Non-Employee Director Compensation Policy, effective as of May 8, 2025 Exhibit 10.1 RELAY THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Relay Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber direct |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 (June 8, 2025) RELAY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39385 47-3923475 (State or other jurisdiction of incorporatio |
|
| June 11, 2025 |
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors Exhibit 99.1 Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors Cambridge, Mass. – June 11, 2025 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| May 5, 2025 |
Exhibit 99.1 Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof |
|
| May 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 23, 2025 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2024 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 FORTHETRANSITIONPERIODFROM TO CommissionFileNumber:001-39385 RELAYTHERAPEUTICS,INC. (ExactnameofRegistrantasspecifiedinitsCha |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEU |
|
| February 26, 2025 |
Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, |
|
| February 26, 2025 |
Registrant's Insider Trading Policy. Exhibit 19.1 RELAY THERAPEUTICS, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Relay Therapeutics, Inc. (the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the appearance of impropriety, to |
|
| February 26, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Relay Therapeutics, Inc. |
|
| February 26, 2025 |
As filed with the Securities and Exchange Commission on February 26, 2025 As filed with the Securities and Exchange Commission on February 26, 2025 Registration No. |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| February 5, 2025 |
BlackRock Advisors, LLC Aperio Group, LLC BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. |
|
| January 13, 2025 |
J.P. Morgan Conference Presentation January 2025 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress and timing of the clinical development of the programs across our portfolio, including the expected |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 11, 2024 |
Exhibit 99.1 Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support pla |
|
| December 11, 2024 |
2024 SABCS – RLY-2608 Data Update December 2024 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2024 |
RLAY / Relay Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 rlay13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) RELAY THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75943R102 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule |
|
| November 6, 2024 |
Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 11, 2024 |
Relay Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Relay Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering |
|
| September 11, 2024 |
Exhibit 1.1 Execution Version RELAY THERAPEUTICS, INC. 28,571,429 Shares of Common Stock, par value $0.001 per share Underwriting Agreement September 10, 2024 Goldman Sachs & Co. LLC TD Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue |
|
| September 11, 2024 |
Relay Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Relay Therapeutics Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 2 |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 11, 2024 |
28,571,429 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-281308 PROSPECTUS SUPPLEMENT (to Prospectus dated August 6, 2024) 28,571,429 Shares Common Stock We are offering 28,571,429 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “RLAY”. The last sale price as reported on The Nasdaq Global Market on September 10, 2024, was |
|
| September 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Relay Therapeutics, Inc. |
|
| September 9, 2024 |
Exhibit 99.1 Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients |
|
| September 9, 2024 |
RLY-2608 Data September 9, 2024 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across |
|
| September 9, 2024 |
Subject To Completion Dated September 9, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-281308 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offe |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 6, 2024 |
Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Relay Therapeutics, Inc. |
|
| August 6, 2024 |
Sales Agreement, dated as of August 6, 2024, between the Registrant and TD Securities (USA) LLC. Exhibit 1.2 RELAY THERAPEUTICS, INC. $250,000,000 COMMON STOCK SALES AGREEMENT August 6, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Relay Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time d |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 6, 2024 |
Exhibit 99.2 Relay Therapeutics Discloses Three New Programs at New Program & Platform Event 3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 |
|
| June 6, 2024 |
Exhibit 99.1 Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 Cambridge, Mass. – June 5, 2024 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a |
|
| June 6, 2024 |
New Program & Platform Event June 2024 Exhibit 99.3 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress and timing of the clinical development of the programs across our portfolio, including the expected therapeuti |
|
| June 3, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 2, 2024 |
Exhibit 99.1 Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 Cambridge, Mass. – May 2, 2024 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 23, 2024 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2023 OR ☐ ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 FORTHETRANSITIONPERIODFROMTO CommissionFileNumber:001-39385 RELAYTHERAPEUTICS,INC. (ExactnameofRegistrantasspecifiedinits |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| February 22, 2024 |
Registrant's Compensation Recovery Policy, adopted as of September 29, 2023. Exhibit 97.1 RELAY THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Relay Therapeutics, Inc. (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers of the Company in accordance wi |
|
| February 22, 2024 |
Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Relay Therapeutics, Inc. (“Relay,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fourth Amende |
|
| February 22, 2024 |
Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approxim |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or other jurisdiction of incorporation) (Commiss |
|
| February 22, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Relay Therapeutics, Inc. |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEU |
|
| February 22, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 14, 2024 |
RLAY / Relay Therapeutics, Inc. / Casdin Capital, LLC Passive Investment SC 13G/A 1 d1082382613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Relay Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75943R102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2024 |
RLAY / Relay Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G 1 rlay13gdec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) RELAY THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75943R102 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule purs |
|
| February 13, 2024 |
RLAY / Relay Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01804-relaytherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Relay Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 75943R102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| January 26, 2024 |
RLAY / Relay Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us75943r1023012624.txt us75943r1023012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Relay Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 75943R102 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 23, 2024 |
RLAY / Relay Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 RelayThInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING RELAY THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 75943R102 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO |
|
| January 10, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424B7 (Form Type) RELAY THERAPEUTICS, INC. |
|
| January 10, 2024 |
2,500,000 Shares Common Stock Offered by the Selling Stockholder 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration Statement No. |
|
| January 8, 2024 |
J.P. Morgan Conference Presentation January 2024 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress and timing of the clinical development of the programs across our portfolio, including the expected |
|
| January 8, 2024 |
Relay Therapeutics Announces $30 Million Private Placement Financing Exhibit 99.2 Relay Therapeutics Announces $30 Million Private Placement Financing Cambridge, Mass. – January 8, 2024 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that it has entered into a securities purchase agreement for a privat |
|
| January 8, 2024 |
Exhibit 10.1 Execution Version RELAY THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of January 8, 2024 (the “Effective Date”), by and among Relay Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers whose name and address is set forth on the signature pages hereof (the “Purchaser”). WHEREAS, the Purchaser d |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 16, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE 424B7 (Form Type) RELAY THERAPEUTICS, INC. |
|
| November 16, 2023 |
1,797,064 Shares Common Stock Offered by the Selling Stockholders 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-258768 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2021) 1,797,064 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus supplement, or the selling stockholders, of 1,797,06 |
|
| November 2, 2023 |
Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runway by approximately |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 2, 2023 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT NO. AR5 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amendment No. AR5 to t |
|
| October 12, 2023 |
RLY-4008 (lirafugratinib) in FGFR2-Altered Solid Tumors October 2023 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress and timing of the clinical development of the programs across our portfolio, inc |
|
| October 12, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 12, 2023 |
Exhibit 99.1 Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors 35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective p |
|
| October 2, 2023 |
RLAY / Relay Therapeutics Inc / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 8, 2023 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT NO. AR4 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amendment No. AR4 to t |
|
| August 8, 2023 |
Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical benefit rate of 86% (6 of 7 evaluable patients) & 1 of 5 patients with measurable disease achieve |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 8, 2023 |
Exhibit 10.3 RELAY THERAPEUTICS, INC. RETENTION AWARD AGREEMENT This Retention Bonus Award Agreement (this “Agreement”) is made and entered into on August 3, 2023 (the “Effective Date”), between Relay Therapeutics, Inc. (the “Company”) and Peter Rahmer (“Employee”). WHEREAS, Employee occupies a key position with the Company and in order to ensure the continued effective conduct of the Company’s bu |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| August 8, 2023 |
Corporate Presentation As of August 08, 2023 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding our strategy, business plans and focus; the progress and timing of the clinical development of the programs across ou |
|
| August 8, 2023 |
Exhibit 10.2 RELAY THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Relay Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber direct |
|
| July 10, 2023 |
RLAY / Relay Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.5 RELAY THERAPEUTICS INC COMMON STOCK Cusip #75943R102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75943R102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,955,196 Item 6: 0 Item 7: 2,956,221 Item 8: 0 Item 9: 2,956,221 Item 11: |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 25, 2023 |
Exhibit 99.1 Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008 Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results Cambridge, Mass. – May 25, 2023 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combin |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 4, 2023 |
Exhibit 99.1 Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor $937.8 million in cash, cash equivalents and investments at end of Q1 2023, expected to fund o |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q be30ou06-30-202s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| April 18, 2023 |
RLY-2608 Initial Clinical Data Presentation at AACR Annual Meeting April 2023 Exhibit 99. |
|
| April 18, 2023 |
Exhibit 99.2 Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target exposures Confirmed partial response in breast cancer patient wit |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEU |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Relay Therapeutics, Inc. |
|
| February 23, 2023 |
Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RELAY THERAPEUTICS, INC. Relay Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Relay Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of S |
|
| February 23, 2023 |
Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced anticipated registrational path Progressed & expanded breast cancer portfolio: Continued |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 9, 2023 |
RLAY / Relay Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Relay Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 75943R102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 9, 2023 |
RLAY / Relay Therapeutics Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 RELAY THERAPEUTICS INC COMMON STOCK Cusip #75943R102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75943R102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,733,481 Item 6: 0 Item 7: 9,733,848 Item 8: 0 Item |
|
| February 3, 2023 |
RLAY / Relay Therapeutics Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING RELAY THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 75943R102 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS |
|
| February 1, 2023 |
RLAY / Relay Therapeutics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us75943r1023013123.txt us75943r1023013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Relay Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 75943R102 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 9, 2023 |
JPM Presentation January 2023 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2022 |
Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society for Medical Oncology (ESMO) Congress $1.1 billion in cash, cash equivalents and investments at the |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 30ou06-30-202s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| October 11, 2022 |
RLAY / Relay Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 RELAY THERAPEUTICS INC COMMON STOCK Cusip #75943R102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75943R102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 11,957,035 Item 6: 0 Item 7: 11,958,212 Item 8: 0 Item 9: 11,958,212 Item |
|
| September 15, 2022 |
Relay Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Relay Therapeutics Announces Proposed Public Offering of Common Stock Cambridge, MA, September 12, 2022 ? Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $300.0 milli |
|
| September 15, 2022 |
Relay Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Relay Therapeutics Announces Pricing of Public Offering of Common Stock Cambridge, MA ? September 12, 2022 ? Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 11,320,755 share |
|
| September 15, 2022 |
Exhibit 1.1 RELAY THERAPEUTICS, INC. 11,320,755 Shares of Common Stock, par value $0.001 per share Underwriting Agreement September 12, 2022 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madiso |
|
| September 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 13, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Relay Therapeutics, Inc. |
|
| September 13, 2022 |
11,320,755 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-258768 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2021) 11,320,755 Shares Common Stock We are offering 11,320,755 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?RLAY?. The last sale price as reported on The Nasdaq Global Market on September 12, 2022, wa |
|
| September 12, 2022 |
ESMO Disclosure Call Materials September 2022 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our str |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 12, 2022 |
Subject To Completion Dated September 12, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-258768 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offe |
|
| September 12, 2022 |
Exhibit 99.1 Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease 88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-na?ve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose Enrollment for the pivotal cohort anticipat |
|
| September 8, 2022 |
Exhibit 99.1 Hollebecque (ESMO 2022) RLY-4008 LBA FINAL Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-na?ve cholangiocarcinoma (CCA): ReFocus trial Antoine Hollebecque1, Mitesh J. Borad2, Lipika Goyal3, Alison M. Schram4, Joon Oh Park5, Philippe Cassier6, Suneel Kamath7, David Tai8, Efrat Dotan9, Richar |
|
| September 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 07, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 1, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424B7 (Form Type) RELAY THERAPEUTICS, INC. |
|
| September 1, 2022 |
301,939 Shares Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-258768 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2021) 301,939 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus supplement, or the selling stockholders, of 301,939 shares o |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 06-30-202s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2022 |
Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June 27th analyst and investor event Cambridge, MA ? August 4, 2022 ? Relay Therapeutics, Inc. (Nasdaq |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 27, 2022 |
Exhibit 99.1 Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-na?ve FGFR2-fusion cholangiocarcinoma (CCA) to potential |
|
| June 27, 2022 |
Analyst & Investor Event June 27, 2022 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, |
|
| May 27, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RELAY THERAPEUTICS, INC. Relay Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of this corporation is Relay Therapeutics, In |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 5, 2022 |
Exhibit 99.1 Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights Initiated the fulvestrant combination arm of the first-in-human trial for RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, and continued to enroll patients in the single agent arm Continued to enroll expansion cohorts for RLY-4008, a potent, selective and oral small molecule inhibitor |
|
| May 5, 2022 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT NO. AR3 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amendment No. AR3 to t |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 5, 2022 |
Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark [***]. First Amendment to COLLABORATION AND LICENSE AGREEMENT between F. Hoffmann-La Roche Ltd Grenzacherstrasse 1 |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| February 24, 2022 |
EX-FILING FEES 4 rlay-exfilingfees6.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Relay Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee R |
|
| February 24, 2022 |
Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with FGFR2-altered tumors Shared preclinical data for RLY-2608, the first known allosteric, pa |
|
| February 24, 2022 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Relay Securities Corporation Massachusetts Relay ML Discovery, LLC Delaware |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEU |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 24, 2022 |
Exhibit 10.2 RELAY THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Relay Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Relay Therapeutics, Inc. (the ?Company?) and its Af |
|
| February 14, 2022 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 14, 2022 |
EXHIBIT 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirec |
|
| February 14, 2022 |
RLAY / Relay Therapeutics Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Relay Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 75943R102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 10, 2022 |
RLAY / Relay Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Relay Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 75943R102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ? |
|
| February 9, 2022 |
RLAY / Relay Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 2 RELAY THERAPEUTICS INC COMMON STOCK Cusip #75943R102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75943R102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,166,515 Item 6: 0 Item 7: 16,206,601 Item 8: 0 Item 9: 16,206,601 Item |
|
| February 4, 2022 |
RLAY / Relay Therapeutics Inc / BlackRock Inc. Passive Investment us75943r1023020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Relay Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 75943R102 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 10, 2022 |
40th Annual J.P. Morgan Healthcare Conference Company Presentation January 2022 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, incl |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Cambridge, MA ? November 10, 2021 ? Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 financial results. ?It?s |
|
| October 14, 2021 |
Relay Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Relay Therapeutics Announces Proposed Public Offering of Common Stock Cambridge, MA ? October 11, 2021 ? Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $350 million |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 14, 2021 |
Exhibit 1.1 RELAY THERAPEUTICS, INC. 13,207,547 Shares of Common Stock, par value $0.001 per share Underwriting Agreement October 12, 2021 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Cowen and Company, LLC Guggenheim Securities, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan |
|
| October 14, 2021 |
Relay Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Relay Therapeutics Announces Pricing of Public Offering of Common Stock Cambridge, MA ? October 12, 2021 ? Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 13,207,547 shares |
|
| October 13, 2021 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-258768 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.001 per share 15,188,679 $26.50 $402,499,993.50 $37,311.75 (1) Includes 1,981, |
|
| October 12, 2021 |
Subject To Completion Dated October 12, 2021 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-258768 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these se |
|
| October 8, 2021 |
Corporate Update Call: Data Presentations at AACR-NCI-EORTC Molecular Targets Conference October 2021 Exhibit 99. |
|
| October 8, 2021 |
Exhibit 99.1 Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3K? RLY-2608 preferentially binds mutant PI3K? at a novel allosteric site discovered by the Dynamo? platform Preclinically, achieved tumor regressions in vivo with significantly reduced impact on glucose metabolism compared to active site inhibitors RLY |
|
| October 8, 2021 |
Exhibit 99.2 Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-na?ve FGFR2 fusion positive |
|
| October 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 25, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-258768 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee Common Stock, par value $0.001 per share 30,732 $31.38 $964,370.16 $105.22 (1) Represents s |
|
| August 13, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-258768 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee Common Stock, par value $0.001 per share 27,904,963 $33.00 $920,863,779 $100,467 (1) Repres |
|
| August 12, 2021 |
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results Company selected RLY-2608 as PI3K? mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H1047X, E542X, and E545X, which affect over 100,000 patients annually in the U.S. Relay Therapeutics and EQRx en |
|
| August 12, 2021 |
Sales Agreement, dated as of August 12, 2021 between the Registrant and Cowen and Company, LLC Exhibit 1.2 RELAY THERAPEUTICS, INC. $300,000,000 COMMON STOCK SALES AGREEMENT August 12, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Relay Therapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the |
|
| August 12, 2021 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.3 RELAY THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certifica |
|
| August 12, 2021 |
Lease by and between the Registrant and BMR-Hampshire, LLC, dated May 26, 2021 Exhibit 10.5 LEASE by and between BMR-HAMPSHIRE, LLC, a Delaware limited liability company and RELAY THERAPEUTICS, INC., a Delaware corporation BioMed Realty form dated 3/8/21 / Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 6 4. Possession and Commencement Date. 7 5. Condition of Premises 9 6. Rentable Area 9 7. Rent 10 8. Rent Adjustments 11 9. Operating Expenses 11 |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| August 12, 2021 |
As filed with the Securities and Exchange Commission on August 12, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2021 Registration No. |
|
| August 12, 2021 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named EX-4.4 4 d191941dex44.htm EX-4.4 Exhibit 4.4 RELAY THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.0 Designation and Terms of Securities 4 Section 2.02 Form |
|
| August 12, 2021 |
Retention Agreement by and between the Registrant and Donald Bergstrom, dated May 10, 2021 Exhibit 10.2 RELAY THERAPEUTICS, INC. RETENTION AWARD AGREEMENT This Retention Bonus Award Agreement (this ?Agreement?) is made and entered effective as of May 10, 2021 (the ?Effective Date?), between Relay Therapeutics, Inc. (the ?Company?) and Donald Bergstrom, M.D., Ph.D. (?Employee?). WHEREAS, Employee occupies a key position with the Company and in order to ensure the continued effective cond |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 12, 2021 |
RLAY / Relay Therapeutics Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 1 RELAY THERAPEUTICS INC COMMON STOCK Cusip #75943R102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75943R102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,522,772 Item 6: 0 Item 7: 10,362,000 Item 8: 0 It |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 19, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 13, 2021 |
Exhibit 10.4 AMENDMENT NO. AR2 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amendment No. AR2 to the Amended and Restated Collaboration and License Agreement (the ?Amendment No. AR2?), effective as of May 12, 2021 (the ?Amendment No. AR2 Effective Date?), is by and between D. E. Shaw Research, LLC, a Delaware limited liability company located at 120 West 45th Street, 39th Floor |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March, 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. |
|
| May 13, 2021 |
Relay Therapeutics Reports First Quarter 2021 Financial Results Exhibit 99.1 Relay Therapeutics Reports First Quarter 2021 Financial Results Cambridge, MA ? May 13, 2021 ? Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today reported first quarter 2021 financial results. ?Since the start of 2021, we have been lase |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 RELAY THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39385 47-3923475 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 13, 2021 |
Retention Agreement by and between the Registrant and Donald Bergstrom, dated May 10, 2021. Exhibit 10.2 RELAY THERAPEUTICS, INC. RETENTION AWARD AGREEMENT This Retention Bonus Award Agreement (this ?Agreement?) is made and entered effective as of May 10, 2021 (the ?Effective Date?), between Relay Therapeutics, Inc. (the ?Company?) and Donald Bergstrom, M.D., Ph.D. (?Employee?). WHEREAS, Employee occupies a key position with the Company and in order to ensure the continued effective cond |
|
| May 6, 2021 |
1,883,487 Shares Common Stock Offered by the Selling Stockholders Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-255583 1,883,487 Shares Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus, or the selling stockholders, of 1,883,487 shares of our common stock, or the Shares. The Shares being offered were issued and so |
|
| May 4, 2021 |
[Signature Page to Acceleration Request] VIA EDGAR May 4, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 3, 2021 |
United States securities and exchange commission logo May 3, 2021 Sanjiv K. Patel, M.D. Chief Executive Officer Relay Therapeutics, Inc. 399 Binney Street, 2nd Floor Cambridge, MA 02139 Re: Relay Therapeutics, Inc. Registration Statement on Form S-1 Filed April 28, 2021 File No. 333-255583 Dear Dr. Patel: This is to advise you that we have not reviewed and will not review your registration stateme |
|
| April 28, 2021 |
Exhibit 10.14 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 22, 2021 (the ?Effective Date?) by and among Relay Therapeutics, Inc., a Delaware corporation (the ?Company?), the equity holders of ZebiAI Therapeutics, Inc., a Delaware corporation (?ZebiAI?), party hereto (each, a ?Stockholder? and, together with any permitted t |
|
| April 28, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 28, 2021. |
|
| April 28, 2021 |
Amended and Restated Non-Employee Director Compensation Policy, effective as of April 1, 2021. Exhibit 10.5 RELAY THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the ?Policy?) of Relay Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber direct |
|
| April 28, 2021 |
Exhibit 10.10 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. AMENDMENT NO. AR1 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amendment No. AR1 to |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 RELAY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39385 47-3923475 (State or other jurisdiction of incorporation) (Commission |
|
| April 16, 2021 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG RELAY THERAPEUTICS, INC., ELIXIR MERGER SUB I, INC., ELIXIR MERGER SUB II, LLC, ZEBIAI THERAPEUTICS, INC., AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, SOLELY IN ITS CAPACITY AS REPRESENTATIVE OF THE SELLERS Dated as of April 15, 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 GENERAL 2 1.2 DEFINITIONS 2 1.3 INTERPRETATION 22 ARTICLE II |
|
| April 16, 2021 |
Conference Call April 2021 Exhibit 99.2 This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condit |
|
| April 16, 2021 |
EX-99.1 Exhibit 99.1 Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a lib |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| March 25, 2021 |
Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Relay Therapeutics, Inc. (?Relay,? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fourth Amende |
|
| March 25, 2021 |
Exhibit 10.10 eXECUTION COPY COnfidential Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark [***]. COLLABORATION AND LICENSE AGREEMENT between GENENTECH, INC. and F. HOFFMANN-LA |
